Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine

Zay Yar Oo(Translational Research Institute), Brian Gabrielli(Translational Research Institute)
Molecular Oncology
May 2, 2019
Cited by 24


Related Papers